Neoplasms

All Conditions

Rare Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Gastrointestinal Agents

All Drugs and Chemicals

Calcium Carbonate

Patients with malignant neuroendocrine tumors

Asher Salmon, M.D., Ph.D.

Hadas Lemberg, PhD

Arik Tzukert, DMD

Benjamin Nisman, PhD

Tamar Peretz, M.D., PhD

Asher Salmon, M.D.

The purpose of this study is to determine whether monitoring of levels of Serological Markers ProGRP, CgA, NSE and Pyruvate Kinase M2 are effective in the Evaluation of Diagnosis, Monitoring Therapeutic Effects and Predicting response to somatostatin analogues in Patients with Malignant Neuroendocrine Tumors.

Assessment of the anatomical spread and disease progression in neuroendocrine tumor patients has become an essential part of disease management, but sometimes in many patients difficult to be measured. Therefore, the evaluation of serum markers could represent a useful tool for monitoring the course of the disease and the response of patients to therapy or palliative treatment.Clinical data considers CgA and NSE as available today blood biomarkers for neuroendocrine tumors.Until now the usefulness of serum ProGRP as a clinical tumor marker has been evaluated mainly in Small Cell Lung Carcinoma, while its role in the management of NE tumors has not been elucidated.Available in the literature limited data suggests that ProGRP may be a potential tumor marker in NE tumors.

Pyruvate kinase type M2 is the key glycolytic regulator in tumor cells.It catalyzes the dephosphorylation of phosphoenolpyruvate to pyruvate with ATP production.The dimeric form of this enzyme (TUM2-PK) has been detected in the blood of patients with different cancers.High TUM2-PK expression was suggested to be an important element of tumor cell metabolism adaptation to an inadequate oxygen and nutrient supply.Recently, it has been shown that somatostatin and its structural analogues pass through cell membrane and actively bind to cytosolic TUM2-PK. In response to this binding TUM2-PK translocates into the nucleus and induce programmed cell death. It is suggested that TUM2-PK enzyme may contribute significantly to response of neuroendocrine tumors to somatostatin analogues.

ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors

Evaluation of Serological Markers ProGRP, CgA, NSE and TUM2-PK in Patients With Malignant Neuroendocrine Tumors

Hadassah Medical Organization

Asher Salmon

Study title	NCT ID	Conditions	Eligibility	Organization
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	NCT00851604	Neuroendocrine ...	18 Years - 90 Years	Hadassah Medical Organization
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	NCT00851604	Neuroendocrine ...	18 Years - 90 Years	Hadassah Medical Organization
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	NCT00851604	Neuroendocrine ...	18 Years - 90 Years	Hadassah Medical Organization

Spots Global Cancer Trial Database for progrp

Every month we try and update this database with for progrp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for progrp

Every month we try and update this database with for progrp cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for progrp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.